T3D Therapeutics, Inc.
T3D-959, an orally delivered small molecule dual nuclear receptor agonist for Alzheimer's disease
- Sector
- Biotech
- Headquarters
- Research Triangle Park, NC
- Founded
- 2013
- Latest Form D
- $6M, Sep 2022
- Total capital
- $36.1M
- Federal grants
- $7.2M
- 8 awards · 2015–2025
- Rank in peer group#89 of 514
- Private capital raised
- $28.9M
- 7 Form D · last Sep 2022
- 50 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 17 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959$204K
- Federal grantHealth and Human S · Phase II · Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959$1M
- Federal grantHealth and Human S · Phase II · Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease$530K
- Federal grantHealth and Human S · Phase II · Clinical Development Enablement – Long Term Rodent Testing of the Carcinogenic Potential of the Alzheimer’s Disease Drug Candidate T3D-959$1.2M
- Federal grantHealth and Human S · Phase II · Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease$1.6M
- Private capital raisedForm D · SEC · 7th filing$6M
- Private capital raisedForm D · SEC · 6th filing$15M
- Private capital raisedForm D · SEC · 5th filing$6M
- Private capital raisedForm D · SEC · 4th filing$711K
- Private capital raisedForm D · SEC · 3rd filing$115K
- Private capital raisedForm D · SEC · 2nd filing$661K
- Private capital raisedForm D · SEC · 1st filing$437K
Show 3 earlier federal awards
- Federal grantHealth and Human S · Phase II · Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$100K
- Federal grantHealth and Human S · Phase II · Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$687K
- Federal grantHealth and Human S · Phase II · Clinical Evaluation of T3D-959 as a Potential Disease Remedial Therapeutic for the Treatment of Alzheimer's Disease$1.8M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grants#89 · top 17%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- John DidsburyResearcherExecutive Officer, Director, PromoterLinked by $7.2M in grants as PI
- Barry BuzoganyDirectorNamed in SEC Form D filings
- Charles LineberryDirectorNamed in SEC Form D filings
- David KeimDirectorNamed in SEC Form D filings
- Donald ParkerDirectorNamed in SEC Form D filings
- John A. GoldenDirectorNamed in SEC Form D filings
Show all 7 people
- Tom MendellDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 17- PendingMethods Of Treating Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesUSPTOApplication 18833293
- PendingMethods Of Treating Diseases And Disorders Resulting From Beta Coronavirus InfectionUSPTOApplication 17244226
- PendingMethods Of Dose Administration For Treating Or Preventing Cognitive Impairment Using Indane Acetic Acid DerivativesUSPTOApplication 15367396
Show all 17 patent records
- Methods Of Treating Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesMar 27, 2025 · Application 18833293Pending
- Methods Of Treating Diseases And Disorders Resulting From Beta Coronavirus InfectionDec 2, 2021 · Application 17244226Pending
- Methods Of Dose Administration For Treating Or Preventing Cognitive Impairment Using Indane Acetic Acid DerivativesJun 7, 2018 · Application 15367396Pending
- Methods Of Treating Or Preventing Cognitive Impairment Using Indane Acetic Acid Derivatives Based On APOE4 GenotypeJun 7, 2018 · Application 15367344Pending
- Methods Of Treating Liver Disease Using Indane Acetic Acid DerivativesMay 3, 2018 · Application 15561434Pending
- Methods Of Treating Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesApplication 63303176Pending
- Methods Of Treating Diseases And Disorders Resulting From Beta Coronavirus InfectionApplication 63017160Pending
- Methods Of Dose Administration For Treating Or Preventing Cognitive Impairment Using Indane Acetic Acid DerivativesApplication PCTUS2017063683Pending
- Methods Of Treating Or Preventing Cognitive Impairment Using Indane Acetic Acid Derivatives Based On APOE4 GenotypeApplication PCTUS2017063618Pending
- Methods Of Treating Liver Disease Using Indane Acetic Acid DerivativesApplication PCTUS2016023694Pending
- Methods Of Identifying And Treating Patients Having Neurodegenerative Disease Based On Plasma Biomarker LevelsApplication 19517153Pending
- Methods Of Identifying And Treating Patients Having Neurodegenerative Disease Based On Plasma Biomarker LevelsApplication PCTUS2024045363Pending
- Methods Of Treating Endothelial Cell And Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesApplication 19504181Pending
- Methods Of Treating Endothelial Cell And Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesApplication PCTUS2024038835Pending
- Methods Of Identifying And Treating Patients Having Neurodegenerative Disease Based On Plasma Biomarker LevelsApplication 63537119Pending
- Methods Of Treating Endothelial Cell And Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesApplication 63528198Pending
- Methods Of Treating Amyloid Related Brain Disorders Using Novel Compounds And AntibodiesApplication PCTUS2023011332Pending
Related companies, and why
- Suono Bio Inc.Similar federal contract value in Biotech · null in contracts
- EnBiotix, Inc.Similar federal contract value in Biotech · null in contracts
- MIMIVAX, LLCSimilar federal contract value in Biotech · null in contracts
- Novosteo Inc.Similar federal contract value in Biotech · null in contracts
- Everest Biolabs, Inc.Similar federal contract value in Biotech · null in contracts
- SIGNUM BIOSCIENCESSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .